Best (but oft-forgotten) practices: The design, analysis, and interpretation of Mendelian randomization studies

American Journal of Clinical Nutrition

Volumn 103, Issue 4, 2016, Pages 965-978

  Haycock, Philip C ^a   Burgess, Stephen ^b   Wade, Kaitlin H ^a   Bowden, Jack ^a,c   Relton, Caroline ^a   Smith, George Davey ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Department of Public Health and Primary Care ^*  (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Causality; Confounding; Evidence synthesis; Mendelian randomization; Observational epidemiology; Reverse causation

Indexed keywords

COST EFFECTIVENESS ANALYSIS; EPIDEMIOLOGY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE POLICY; MENDELIAN RANDOMIZATION ANALYSIS; PLEIOTROPY; PROPHYLAXIS; PUBLIC HEALTH; REVIEW; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; GENETIC ASSOCIATION STUDY; GENETIC DATABASE; GENETICS; HUMAN; METABOLISM; METHODOLOGY; PROCEDURES; REPRODUCIBILITY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DATABASES, GENETIC; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INTERLEUKIN-6; MENDELIAN RANDOMIZATION ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-6; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RISK FACTORS;

EID: 84962675367     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.115.118216     Document Type: Review

References (80)

1. Phillips AN, Davey Smith G. How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991;44:1223-31.
2. Davey Smith G, Ebrahim S. Data dredging, bias, or confounding. BMJ 2002;325:1437-8.
3. Hill AB. The environment and disease: Association or causation? Proc R Soc Med 1965;58:295-300.
4. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
5. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: Meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014;349:g4379.
6. Myung S-K, Ju W, Cho B, Oh S-W, Park SM, Koo B-K, Park B-J. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: Systematic review and meta-analysis of randomised controlled trials. BMJ 2013;346:f10.
7. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6.
8. Knekt P, Ritz J, Pereira MA, O'Reilly EJ, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, Hallmans G, Liu S, et al. Antioxidant vitamins and coronary heart disease risk: A pooled analysis of 9 cohorts. Am J Clin Nutr 2004;80:1508-20.
9. Davey Smith G, Ebrahim S. "Mendelian randomization": Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
10. Bowden RJ, Turkington DA. Instrumental variables. Perth (Australia): Cambridge University Press; 1990.
11. Davey Smith G, Hemani G. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014; 23:R89-98.
12. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA, Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis. J Am Coll Cardiol 2012;60:2631-9.
13. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, Engert JC, Clarke R, Davey Smith G, Nordestgaard BG, et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ 2011;342:d548.
14. Zacho J, Tybjærg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908.
15. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, et al. Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study. Lancet 2012;380:572-80.
16. Palmer TM, Nordestgaard BG, Benn M, Tybjærg-hansen A, Davey Smith G, Lawlor DA, Timpson NJ. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. BMJ 2013;347:f4262.
17. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, et al. Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies. Lancet 2010;375:1634-9.
18. Erratum in: Lancet 2010;376(9735):90.
19. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, Dale CE, Padmanabhan S, Finan C, Swerdlow DI, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015;36:539-50.
20. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376: 1670-81.
21. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133-63.
22. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res 2007;16:309-30.
23. Glymour MM, Tchetgen Tchetgen EJ, Robins JM. Credible Mendelian randomization studies: Approaches for evaluating the instrumental variable assumptions. Am J Epidemiol 2012;175:332-9.
24. Wade KH, Timpson N, Davey Smith G. Mendelian randomization studies: Recent methodologic developments [cited 2015 Jun 12]. Available from: Http://www.acc.org/latest-in-cardiology/articles/2015/06/11/14/25/mendelian-randomization-studies-recent-methodologicaldevelopments.
25. Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, Poole C. Illustrating bias due to conditioning on a collider. Int J Epidemiol 2010;39:417-20.
26. Blakely T, McKenzie S, Carter K. Misclassification of the mediator matters when estimating indirect effects. J Epidemiol Community Health 2013;67:458-66.
27. le Cessie S, Debeij J, Rosendaal FR, Cannegieter SC, Vandenbroucke JP. Quantification of bias in direct effects estimates due to different types of measurement error in the mediator. Epidemiology 2012;23: 551-60.
28. VanderWeele TJ. Invited commentary: Structural equation models and epidemiologic analysis. Am J Epidemiol 2012;176:608-12.
29. Cole DA, Preacher KJ. Manifest variable path analysis: Potentially serious and misleading consequences due to uncorrected measurement error. Psychol Methods 2014;19:300-15.
30. VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P. Methodological challenges in Mendelian randomization. Epidemiology 2014;25:427-35.
31. Wagner GP, Zhang J. The pleiotropic structure of the genotypephenotype map: The evolvability of complex organisms. Nat Rev Genet 2011;12:204-13.
32. Burgess S, Thompson SG. Bias in causal estimates from Mendelian randomization studies with weak instruments. Stat Med 2011;30:1312-23.
33. Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol 2014;43:922-9.
34. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 2015;518: 197-206.
35. Göring HH, Terwilliger JD, Blangero J. Large upward bias in estimation of locus-specific effects from genomewide scans. Am J Hum Genet 2001;69:1357-69.
36. Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NHH, Steffensen R, Sillesen H, Jensen G, Nordestgaard BG. Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation 2004;109:59-65.
37. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, et al. Interleukin-6 receptor pathways in coronary heart disease: A collaborative metaanalysis of 82 studies. Lancet 2012;379:1205-13.
38. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet 2012;379:1214-24.
39. Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: Systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010;55:2160-7.
40. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein( a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.
41. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-28.
42. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331-9.
43. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 2008;19:369-77.
44. Simó JM, Joven J, Vilella E, Ribas M, Pujana MA, Sundaram IM, Hammel JP, Hoover-Plow JL. Impact of apolipoprotein(a) isoform size heterogeneity on the lysine binding function of lipoprotein(a) in early onset coronary artery disease. Thromb Haemost 2001;85:412-7.
45. Xia J, May LF, Koschinsky ML. Characterization of the basis of lipoprotein[ a] lysine-binding heterogeneity. J Lipid Res 2000;41:1578-84.
46. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991;115:209-18.
47. Smith EB, Crosbie L. Does lipoprotein(a) (Lp(a)) complete with plasminogen in human atherosclerotic lesions and thrombi? Atherosclerosis 1991;89:127-36.
48. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5.
49. Taylor AE, Davies NM, Ware JJ, VanderWeele T, Davey Smith G, Munafò MR. Mendelian randomization in health research: Using appropriate genetic variants and avoiding biased estimates. Econ Hum Biol 2014;13:99-106.
50. Munafò MR, Timofeeva MN, Morris RW, Prieto-Merino D, Sattar N, Brennan P, Johnstone EC, Relton C, Johnson PCD, Walther D, et al. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst 2012;104: 740-8.
51. Dai JY, Zhang XC. Mendelian randomization studies for a continuous exposure under case-control sampling. Am J Epidemiol 2015;181:440-9.
52. Bowden J, Vansteelandt S. Mendelian randomization analysis of casecontrol data using structural mean models. Stat Med 2011;30:678-94.
53. Harbord RM, Didelez V, Palmer TM, Meng S, Sterne JAC, Sheehan NA. Severity of bias of a simple estimator of the causal odds ratio in Mendelian randomization studies. Stat Med 2013;32:1246-58.
54. Vansteelandt S, Bowden J, Babanezhad M, Goetghebeur E. On instrumental variables estimation of causal odds ratios. Stat Sci 2011;26: 403-22.
55. Burgess S. Identifying the odds ratio estimated by a two-stage instrumental variable analysis with a logistic regression model. Stat Med 2013;32:4726-47.
56. Angrist JD, Imbens GW. Two-stage least squares estimation of average causal effects in models with variable treatment intensity. J Am Stat Assoc 1995;90:431-42.
57. Thomas DC, Lawlor DA, Thompson JR. Re: Estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al. Ann Epidemiol 2007;17:511-3.
58. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG; EPIC-InterAct Consortium. Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors. Eur J Epidemiol 2015;30:543-52.
59. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: Subsample and 2-sample instrumental variable estimators. Am J Epidemiol 2013;178:1177-84.
60. Psychiatric Genomics Consortium [Internet; cited 2015 Oct 1.] Available from: Http://www.med.unc.edu/pgc.
61. Timpson NJ, Nordestgaard BG, Harbord RM, Zacho J, Frayling TM, Tybjærg-Hansen A, Davey Smith G. C-reactive protein levels and body mass index: Elucidating direction of causation through reciprocal Mendelian randomization. Int J Obes (Lond) 2011;35:300-8.
62. Peng C-H, Jiang Y-Z, Tai A-S, Liu C-B, Peng S-C, Liao C-T, Yen T-C, Hsieh W-P. Causal inference of gene regulation with subnetwork assembly from genetical genomics data. Nucleic Acids Res 2014;42: 2803-19.
63. Neto EC, Keller MP, Attie AD, Yandell BS. Causal graphical models in systems genetics: A unified framework for joint inference of causal network and genetic architecture for correlated phenotypes. Ann Appl Stat 2010;4:320-39.
64. Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: A strategy for establishing the causal role of epigenetic processes in pathways to disease. Int J Epidemiol 2012;41:161-76.
65. Varbo A, Benn M, Davey Smith G, Timpson NJ, Tybjaerg-Hansen A, Nordestgaard BG. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res 2015;116:665-73.
66. Burgess S, Daniel RM, Butterworth AS, Thompson SG; EPIC-InterAct Consortium. Network Mendelian randomization: Using genetic variants as instrumental variables to investigate mediation in causal pathways. Int J Epidemiol 2015;44:484-95.
67. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, Sulem P, Rafnar T, Esko T, Walter S, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010;42:448-53.
68. Chen L, Davey Smith G, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: A systematic review implementing a Mendelian randomization approach. PLoS Med 2008;5:e52.
69. Hashibe M, Boffetta P, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, Janout V, Fabiánová E, Bencko V, Moullan N, et al. Evidence for an important role of alcohol-and aldehyde-metabolizing genes in cancers of the upper aerodigestive tract. Cancer Epidemiol Biomarkers Prev 2006;15:696-703.
70. Bergholdt HK, Nordestgaard BG, Ellervik C. Milk intake is not causally associated with diabetes-a Mendelian randomization study in 97,811 Danish individuals. Am J Clin Nutr 2015;102:487-96.
71. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Day I, Ebrahim S. Clustered environments and randomized genes: A fundamental distinction between conventional and genetic epidemiology. PLoS Med 2007;4:e352.
72. Sargan J. The estimation of economic relationships using instrumental variables. Econom J Econom Soc. 1958;26:393-415.
73. Bowden J, Davey Smith G, Burgess S, Smith G, Burgess S, Unit M. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44: 512-25.
74. Han C. Detecting invalid instruments using L1-GMM. Econ Lett 2008; 101:285-7.
75. Kang H, Zhang A, Cai TT, Small DS. Instrumental variables estimation with some invalid instruments and its application to Mendelian randomization. J Am Stat Assoc. Available from: Http://amstat.tandfonline. com/doi/abs/10.1080/01621459.2014.994705.
76. Bowden J, Haycock PC, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. In press.
77. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein E. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA 2012;308:2497-506.
78. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
79. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, et al. The support of human genetic evidence for approved drug indications. Nat Genet 2015;47:856-60.
80. Shin S-Y, Fauman EB, Petersen A-K, Krumsiek J, Santos R, Huang J, Arnold M, Erte I, Forgetta V, Yang T-P, et al. An atlas of genetic influences on human blood metabolites. Nat Genet 2014;46:543-50.